Skip to Content
Merck
  • The stem cell potential and multipotency of human adipose tissue-derived stem cells vary by cell donor and are different from those of other types of stem cells.

The stem cell potential and multipotency of human adipose tissue-derived stem cells vary by cell donor and are different from those of other types of stem cells.

Cells, tissues, organs (2015-04-01)
Hyun Jin Yang, Ki-Joo Kim, Min Kyoung Kim, Su Jin Lee, Yeon Hee Ryu, Bommie F Seo, Deuk-Young Oh, Sang-Tae Ahn, Hee Young Lee, Jong Won Rhie
ABSTRACT

Human adipose tissue-derived mesenchymal stem cells (AT-MSCs) from various sites are applied in tissue engineering and cell therapy. The condition of AT-MSCs depends on the donor's age, body mass index (BMI), and gender. AT-MSCs from 66 human donors were analyzed, and the cells were sorted according to donor age (10-19 years: n = 1; 20-29 years: n = 5; 30-39 years: n = 12; 40-49 years: n = 22; 50-59 years: n = 12; 60-69 years: n = 9, and 70 years or older: n = 5), BMI (under 25, 25-30, and over 30), and gender (19 males and 48 females). Additionally, AT-MSCs were compared to bone marrow MSCs and chorionic tissue-derived MSCs. We measured the MSC yield, growth rate, colony-forming units, multipotency, and surface antigens. AT-MSC proliferation was greater in cells isolated from individuals aged less than 30 years compared to the proliferation of AT-MSCs from those over 50 years old. BMI was correlated with osteogenic differentiation potency; increased BMI enhanced osteogenesis. Adipogenic differentiation was more strongly induced in cells isolated from donors aged less than 30 years compared to those isolated from other age groups. Also, a BMI above 30 was associated with enhanced adipogenic differentiation compared to cells isolated from individuals with a BMI below 25. Bone marrow MSCs were strongly induced to differentiate along both osteogenic and adipogenic lineages, whereas AT-MSCs predominantly differentiated into the chondrogenic lineage. Therefore, the type of regeneration required and variations among potential donors must be carefully considered when selecting MSCs for use in applied tissue engineering or cell therapy.

MATERIALS
Product Number
Brand
Product Description

Dexamethasone, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Guanidine hydrochloride, ≥99% (titration), organic base and chaeotropic agent
USP
Dexamethasone, United States Pharmacopeia (USP) Reference Standard
Supelco
Dexamethasone, Pharmaceutical Secondary Standard; Certified Reference Material
Dexamethasone, British Pharmacopoeia (BP) Assay Standard
Sigma-Aldrich
Guanidine hydrochloride, anhydrous, free-flowing, Redi-Dri, ≥99%
Sigma-Aldrich
Guanidine hydrochloride, ≥99.0% (AT)
Sigma-Aldrich
Guanidine hydrochloride, Molecular Biology, ≥99%
Sigma-Aldrich
Dexamethasone, powder, BioReagent, suitable for cell culture, ≥97%
Sigma-Aldrich
Guanidine hydrochloride, BioUltra, Molecular Biology, ≥99.5% (AT)
Sigma-Aldrich
Guanidine hydrochloride, ≥98%
Sigma-Aldrich
Dexamethasone, tested according to Ph. Eur.
Supelco
Dexamethasone, VETRANAL®, analytical standard
Sigma-Aldrich
Dexamethasone, meets USP testing specifications
Sigma-Aldrich
Dexamethasone, powder, γ-irradiated, BioXtra, suitable for cell culture, ≥80% (HPLC)
Sigma-Aldrich
Dexamethasone, ≥98% (HPLC), powder
Dexamethasone for system suitability, European Pharmacopoeia (EP) Reference Standard
Cetylpyridinium chloride, European Pharmacopoeia (EP) Reference Standard
USP
Cetylpyridinium chloride, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Guanidine hydrochloride solution, Colorless liquid, 7.8 - 8.3 M, pH- 4.5 - 5.5
Sigma-Aldrich
Guanidine hydrochloride solution, BioUltra, ~8 M in H2O
Sigma-Aldrich
Cetylpyridinium chloride, meets USP testing specifications
Dexamethasone for peak identification, European Pharmacopoeia (EP) Reference Standard